FibroGen CEO Resigns Amid Clinical Losing Streak, Layoffs

Tuesday, FibroGen announced that after three years at the helm, CEO Enrique Conterno had resigned “due to personal reasons.”

While FibroGen’s board searches for a permanent replacement, Chief Commercial Officer Thane Wettig will serve as interim CEO of the company, with Conterno taking the role of his special advisor during the transition period. The leadership transition took effect Sunday.